.Planet Health Institution. Obesity and also obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Health Condition Risk Aspect Cooperation. Worldwide trends in undersized and excessive weight from 1990 to 2022: a pooled evaluation of 3663 population-representative research studies along with 222 thousand kids, adolescents, and grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.International Trouble Disease Collaborators. Global, local, as well as nationwide concern of diabetic issues from 1990 to 2021, along with forecasts of frequency to 2050: a step-by-step analysis for the Global Worry of Health Condition Research 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Renal Day Steerage Board. Excessive weight and kidney health condition: concealed effects of the epidemic. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A systematic assessment and meta-analysis proposes obesity forecasts start of severe renal condition in the basic population. Renal Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et al. Obesity as well as constant kidney health condition.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Venue, J. E., do Carmo, J. M., da Silva, A.
A., Wang, Z. & Hall, M. E.
Being overweight, kidney disorder and high blood pressure: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Renal Disease: Improving Worldwide Results CKD Workplace Team.
KDIGO 2024 Scientific Process Tip for the evaluation and also administration of chronic renal condition. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Kidney Ailment: Improving Worldwide End Results Diabetes The Office Group. KDIGO 2022 Professional Method Guideline for diabetes mellitus monitoring in constant kidney ailment. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google.com Scholaru00c2.Oshima, M. et al.
Early adjustment in albuminuria along with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc review coming from the support test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an intended for renoprotection in individuals along with style 2 diabetic nephropathy: trainings from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et cetera. Is a reduction in albuminuria linked with renal as well as heart security?
A post hoc evaluation of the height test. Diabetic issues Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney ailment: a testimonial of their kidney as well as heart defense. Am.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 and the renal: from anatomy to pharmacology as well as outcomes in diabetic issues.
Nat. Rev. Nephrol.
Thirteen, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and heart results in individuals along with type 2 diabetic issues. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et al. Semaglutide and heart end results in weight problems without diabetic issues. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on chronic kidney disease in clients along with kind 2 diabetes. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et cetera.
Lasting renal end results of semaglutide in obesity and heart disease in the SELECT trial. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of semaglutide on albuminuria as well as kidney functionality in people with over weight or even excessive weight with or even without kind 2 diabetic issues: preliminary study from the action 1, 2, and 3 tests.
Diabetes mellitus Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Medicine Man, A. M.
et al. Impact of the glucagon-like peptide-1 receptor agonists semaglutide as well as liraglutide on renal results in clients along with type 2 diabetic issues: pooled evaluation of SUSTAIN 6 and also LEADER. Flow 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et al.
Result of semaglutide on kidney function all over various degrees of standard HbA1c, high blood pressure, physical body weight and albuminuria in SUSTAIN 6 and also leader 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus blood insulin glargine in individuals with style 2 diabetes and also moderate-to-severe constant kidney illness (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Adjustment in albuminuria as a surrogate endpoint for progress of renal illness: a meta-analysis of treatment effects in randomised medical trials. Lancet Diabetes Mellitus Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Effects of semaglutide with and also without concomitant SGLT2 inhibitor usage in individuals with kind 2 diabetes mellitus and also constant renal ailment in the circulation test. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and also protection results along with GLP-1 receptor agonists alone as well as in mix along with SGLT2 inhibitors in style 2 diabetic issues: a systematic review as well as meta-analysis.
Circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Effectiveness and also safety and security of SGLT2 inhibitors along with as well as without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised regulated tests. Lancet Diabetes Mellitus Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Effects of tirzepatide versus the hormone insulin glargine on kidney results in kind 2 diabetic issues in the SURPASS-4 trial: post-hoc evaluation of an open-label, randomised, phase 3 trial.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et cetera. Body weight and eGFR during the course of dulaglutide treatment in kind 2 diabetes as well as moderate-to-severe severe renal ailment (AWARD-7).
Diabetic issues Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Impacts of tirzepatide versus blood insulin glargine on cystatin c-based kidney feature: a SURPASS-4 article hoc study. Diabetes Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetic Issues Treatment (American Diabetes Association, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Impacts of bariatric surgery on kidney function in obese clients: a systematic review and also meta evaluation.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The effects of bariatric surgical treatment on renal outcomes: a systematic analysis as well as meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The measured glomerular purification price (mGFR) before and also 6 months after bariatric surgical treatment: an aviator study. Nephrol.
Ther. Thirteen, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et cetera. Adiponectin lessens glomerular endothelial glycocalyx disturbance as well as restores glomerular barricade function in a mouse design of type 2 diabetes. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration related to diabetes mellitus as well as excessive weight in human health condition. Realm J.
Diabetic Issues 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Measuring albuminuria in individuals with obesity: difficulties of the urinary albumin-creatinine proportion. Kidney Medication.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in adults along with over weight or being overweight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et al. An additional accurate technique to estimate glomerular filtration rate from serum creatinine: a brand-new prophecy formula.
Alteration of Diet Regimen in Kidney Disease Study Group. Ann. Intern.
Medication. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS approach for iohexol resolution in individual EDTA and lithium-heparin blood, individual urine as well as in goat- and swine EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et cetera.
Effectiveness as well as safety of aldosterone synthase hangup along with as well as without empagliflozin for constant kidney ailment: a randomised, regulated, phase 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et al. Effectiveness of an unique inhibitor of general adherence protein-1 in minimizing albuminuria in individuals with diabetic person kidney health condition (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Mellitus Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in mixture along with dapagliflozin compared to dapagliflozin in patients along with severe renal illness (ZENITH-CKD): a multicentre, randomised, active-controlled, period 2b, clinical trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Effect of avenciguat on albuminuria in individuals with CKD: 2 randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in people with IgA nephropathy: a prespecified meantime review due to a randomised, double-blind, active-controlled medical test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.